Overview Dividends

(KURA) Kura Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US50127T1097

Menin Inhibitor, Farnesyl Transferase Inhibitor, Tipifarnib

EPS (Earnings per Share)

EPS (Earnings per Share) of KURA over the last years for every Quarter: "2020-09": -0.42, "2020-12": -0.45, "2021-03": -0.46, "2021-06": -0.51, "2021-09": -0.5, "2021-12": -0.49, "2022-03": -0.49, "2022-06": -0.52, "2022-09": -0.53, "2022-12": -0.49, "2023-03": -0.5, "2023-06": -0.53, "2023-09": -0.5, "2023-12": -0.55, "2024-03": -0.59, "2024-06": -0.59, "2024-09": -0.63, "2024-12": -0.22, "2025-03": -0.66, "2025-06": -0.75, "2025-09": -0.85,
EPS Growth (3y CAGR): -51.50%
EPS Trend (3y Corr): -45.2%
Last SUE: -0.48σ
Qual. Beats: 0

Revenue

Revenue of KURA over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.27, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 53.883, 2025-03: 14.108, 2025-06: 15.288, 2025-09: 20.75,
Revenue Growth (3y CAGR): 77.58%
Revenue Trend (3y Corr): 78.4%
Last SUE: -1.39σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 56.5%
Value at Risk 5%th 84.0%
Relative Tail Risk -9.69%
Reward TTM
Sharpe Ratio -0.21
Alpha -44.90
Character TTM
Hurst Exponent 0.462
Beta 0.940
Beta Downside 0.970
Drawdowns 3y
Max DD 76.46%
Mean DD 36.81%
Median DD 31.25%

Description: KURA Kura Oncology October 23, 2025

Kura Oncology Inc. (NASDAQ:KURA) is a clinical-stage biopharma focused on targeted cancer therapies. Its lead assets are ziftomenib, a selective menin-KMT2A inhibitor for genetically defined acute leukemias, tipifarnib (combined with alpelisib) for PIK3CA-driven head-and-neck squamous cell carcinoma, and KO-2806, a novel farnesyl-transferase inhibitor for solid tumors. The company has partnered with Novartis (tipifarnib + alpelisib), Kyowa Kirin (oral menin inhibitor development and commercialization) and Mirati Therapeutics (KO-2806 + adagrasib in KRAS-G12C NSCLC). Headquarters are in San Diego, California.

Key recent metrics: as of the latest 10-Q, Kura reported cash and cash equivalents of roughly $150 million, giving it an estimated 12-month runway at its current burn rate of $12-$15 million per quarter. The AML market is projected to exceed $7 billion by 2028, providing a sizable addressable base for ziftomenib. Additionally, the biotech sector’s R&D tax credit and strong venture financing environment have been supporting cash-flow-positive pipelines for companies at Kura’s stage.

If you want a deeper, data-driven look at Kura’s valuation assumptions and scenario analysis, the ValueRay platform offers a transparent model you can explore at your own pace.

KURA Stock Overview

Market Cap in USD 975m
Sub-Industry Biotechnology
IPO / Inception 2015-09-22
Return 12m vs S&P 500 -39.2%
Analyst Rating 4.53 of 5

KURA Dividends

Currently no dividends paid

KURA Growth Ratios

Metric Value
CAGR 3y -10.37%
CAGR/Max DD Calmar Ratio -0.14
CAGR/Mean DD Pain Ratio -0.28
Current Volume 1744.1k
Average Volume 1670k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-216.9m TTM) > 0 and > 6% of Revenue (6% = 6.24m TTM)
FCFTA 0.13 (>2.0%) and ΔFCFTA 48.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 480.0% (prev 33.3k%; Δ -32.8kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.14 (>3.0%) and CFO 87.8m > Net Income -216.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.6m) change vs 12m ago 0.80% (target <= -2.0% for YES)
Gross Margin 96.50% (prev 32.44%; Δ 64.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 18.44% (prev 0.27%; Δ 18.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -136.5 (EBITDA TTM -220.8m / Interest Expense TTM 1.57m) >= 6 (WARN >= 3)

Altman Z'' -5.81

(A) 0.77 = (Total Current Assets 620.7m - Total Current Liabilities 121.3m) / Total Assets 649.4m
(B) -1.68 = Retained Earnings (Balance) -1.09b / Total Assets 649.4m
warn (B) unusual magnitude: -1.68 — check mapping/units
(C) -0.38 = EBIT TTM -214.2m / Avg Total Assets 564.1m
(D) -2.68 = Book Value of Equity -1.09b / Total Liabilities 406.8m
Total Rating: -5.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 54.03

1. Piotroski 3.0pt = -2.0
2. FCF Yield 18.68% = 5.0
3. FCF Margin 79.89% = 7.50
4. Debt/Equity 0.08 = 2.50
5. Debt/Ebitda 0.34 = 2.41
6. ROIC - WACC (= -72.14)% = -12.50
7. RoE -65.42% = -2.50
8. Rev. Trend 78.44% = 5.88
9. EPS Trend -45.16% = -2.26

What is the price of KURA shares?

As of November 20, 2025, the stock is trading at USD 11.08 with a total of 1,744,140 shares traded.
Over the past week, the price has changed by +3.65%, over one month by +10.91%, over three months by +48.13% and over the past year by -30.92%.

Is KURA a buy, sell or hold?

Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KURA price?

Issuer Target Up/Down from current
Wallstreet Target Price 31.6 185.2%
Analysts Target Price 31.6 185.2%
ValueRay Target Price 11.7 6%

KURA Fundamental Data Overview November 17, 2025

Market Cap USD = 975.0m (975.0m USD * 1.0 USD.USD)
P/S = 9.3727
P/B = 4.0201
Beta = 0.229
Revenue TTM = 104.0m USD
EBIT TTM = -214.2m USD
EBITDA TTM = -220.8m USD
Long Term Debt = 5.34m USD (from longTermDebt, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 19.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.8m USD (from netDebt column, last quarter)
Enterprise Value = 444.8m USD (975.0m + Debt 19.5m - CCE 549.7m)
Interest Coverage Ratio = -136.5 (Ebit TTM -214.2m / Interest Expense TTM 1.57m)
FCF Yield = 18.68% (FCF TTM 83.1m / Enterprise Value 444.8m)
FCF Margin = 79.89% (FCF TTM 83.1m / Revenue TTM 104.0m)
Net Margin = -208.5% (Net Income TTM -216.9m / Revenue TTM 104.0m)
Gross Margin = 96.50% ((Revenue TTM 104.0m - Cost of Revenue TTM 3.64m) / Revenue TTM)
Gross Margin QoQ = 84.52% (prev 98.53%)
Tobins Q-Ratio = 0.69 (Enterprise Value 444.8m / Total Assets 649.4m)
Interest Expense / Debt = 2.02% (Interest Expense 393.0k / Debt 19.5m)
Taxrate = -0.0% (0.0 / -74.1m)
NOPAT = -214.2m (EBIT -214.2m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 5.12 (Total Current Assets 620.7m / Total Current Liabilities 121.3m)
Debt / Equity = 0.08 (Debt 19.5m / totalStockholderEquity, last quarter 242.5m)
Debt / EBITDA = 0.34 (negative EBITDA) (Net Debt -75.8m / EBITDA -220.8m)
Debt / FCF = -0.91 (Net Debt -75.8m / FCF TTM 83.1m)
Total Stockholder Equity = 331.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.40% (Net Income -216.9m / Total Assets 649.4m)
RoE = -65.42% (Net Income TTM -216.9m / Total Stockholder Equity 331.5m)
RoCE = -63.60% (EBIT -214.2m / Capital Employed (Equity 331.5m + L.T.Debt 5.34m))
RoIC = -62.80% (negative operating profit) (NOPAT -214.2m / Invested Capital 341.1m)
WACC = 9.33% (E(975.0m)/V(994.5m) * Re(9.48%) + D(19.5m)/V(994.5m) * Rd(2.02%) * (1-Tc(-0.0)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.46%
[DCF Debug] Terminal Value 73.93% ; FCFE base≈83.1m ; Y1≈86.7m ; Y5≈100.2m
Fair Price DCF = 15.75 (DCF Value 1.37b / Shares Outstanding 87.0m; 5y FCF grow 4.64% → 3.0% )
EPS Correlation: -45.16 | EPS CAGR: -51.50% | SUE: -0.48 | # QB: 0
Revenue Correlation: 78.44 | Revenue CAGR: 77.58% | SUE: -1.39 | # QB: 0

Additional Sources for KURA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle